Immunosuppression by co-stimulatory molecules: Inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice

Chemical Biology and Drug Design

Volumn 82, Issue 1, 2013, Pages 106-118

  Gokhale, Ameya ^a   Kanthala, Shanthi ^a   Latendresse, John ^b   Taneja, Veena ^c   Satyanarayanajois, Seetharama ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c MAYO CLINIC   (United States)

Author keywords

CD2; CD58; Collagen induced arthritis; Cyclic peptide; Docking; Immune response; Protein protein interaction

Indexed keywords

ANTIRHEUMATIC AGENT; CD2 ANTIGEN; CD48 ANTIGEN; CYCLIC PEPTIDE 6; CYCLOPEPTIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL ADHESION; CELL STRAIN CACO 2; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE COURSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LEUKEMIA CELL LINE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, CD58; ARTHRITIS, EXPERIMENTAL; BINDING SITES; CACO-2 CELLS; CELL ADHESION; FLUORESCENT DYES; HUMANS; IMMUNOSUPPRESSION; JURKAT CELLS; MICE; MICE, INBRED DBA; MICE, TRANSGENIC; MOLECULAR DOCKING SIMULATION; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

ANIMALIA; MUS; RODENTIA;

EID: 84879524742     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12138     Document Type: Article

References (55)

1. Bretscher P.A. (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA;96:185-190.
2. van der Merwe P.A., Davis S.J. (2003) Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol;21:659-684.
3. Dustin M.L., Olszowy M.W., Holdorf A.D., Li J., Bromley S., Desai N., Widder P., Rosenberger F., van der Merwe P.A., Allen P.M., Shaw A.S. (1998) A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell;94:667-677.
4. Davis S.J., Ikemizu S., Evans E.J., Fugger L., Bakker T.R., van der Merwe P.A. (2003) The nature of molecular recognition by T cells. Nat Immunol;4:217-224.
5. Ellis C.N., Krueger G.G. (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med;345:248-255.
6. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K.M., Krueger J.G. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA;102:2075-2080.
7. Strand V. (2001) New therapies in development for autoimmune diseases: their rationale for combination treatment. Springer Semin Immunopathol;23:43-61.
8. Anderson M.E., Siahaan T.J. (2003) Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides;24:487-501.
9. Webber A., Hirose R., Vincenti F. (2011) Novel strategies in immunosuppression: issues in perspective. Transplantation;91:1057-1064.
10. Mrowietz U. (2002) Treatment targeted to cell surface epitopes. Clin Exp Dermatol;27:591-596.
11. Hale L.P., Martin M.E., McCollum D.E., Nunley J.A., Springer T.A., Singer K.H., Haynes B.F. (1989) Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum;32:22-30.
12. Kraan M.C., van Kuijk A.W., Dinant H.J., Goedkoop A.Y., Smeets T.J., de Rie M.A., Dijkmans B.A., Vaishnaw A.K., Bos J.D., Tak P.P. (2002) Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum;46:2776-2784.
13. Raychaudhuri S., Thomson B.P., Remmers E.F., Eyre S., Hinks A., Guiducci C., Catanese J.J., et al. (2009) Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet;41:1313-1318.
14. Bierer B.E., Burakoff S.J. (1988) T cell adhesion molecules. FASEB J;2:2584-2590.
15. Hoffmann J.C., Bayer B., Zeidler H. (1996) Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol;104:460-466.
16. Cemerski S., Shaw A. (2006) Immune synapses in T-cell activation. Curr Opin Immunol;18:298-304.
17. Snanoudj R., Zuber J., Legendre C. (2010) Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs;70:2121-2131.
18. Liossis S.N., Sfikakis P.P. (2004) Costimulation blockade in the treatment of rheumatic diseases. BioDrugs;18:95-102.
19. Vincenti F., Kirk A.D. (2008) What's next in the pipeline. Am J Transplant;8:1972-1981.
20. Satyanarayanajois S.D., Buyuktimkin B., Gokhale A., Ronald S., Siahaan T.J., Latendresse J.R. (2010) A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model. Chem Biol Drug Des;76:234-244.
21. Liu J., Li C., Ke S., Satyanarayanajois S.D. (2007) Structure-based rational design of beta-hairpin peptides from discontinuous epitopes of cluster of differentiation 2 (CD2) protein to modulate cell adhesion interaction. J Med Chem;50:4038-4047.
22. Liu J., Chow V.T., Jois S.D. (2004) A novel, rapid and sensitive heterotypic cell adhesion assay for CD2-CD58 interaction, and its application for testing inhibitory peptides. J Immunol Methods;291:39-49.
23. Giddu S., Subramanian V., Yoon H.S., Satyanarayanajois S.D. (2009) Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem;52:726-736.
24. Li C., Satyanarayanajois S.D. (2007) Structure-function studies of peptides for cell adhesion inhibition: identification of key residues by alanine mutation and peptide-truncation approach. Peptides;28:1498-1508.
25. Jining L., Makagiansar I., Yusuf-Makagiansar H., Chow V.T., Siahaan T.J., Jois S.D. (2004) Design, structure and biological activity of beta-turn peptides of CD2 protein for inhibition of T-cell adhesion. Eur J Biochem;271:2873-2886.
26. Gokhale A., Weldeghiorghis T.K., Taneja V., Satyanarayanajois S.D. (2011) Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58. J Med Chem;54:5307-5319.
27. Ianelli C.J., Edson C.M., Thorley-Lawson D.A. (1997) A ligand for human CD48 on epithelial cells. J Immunol;159:3910-3920.
28. Corradin G., Etlinger H.M., Chiller J.M. (1977) Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice. J Immunol;119:1048-1053.
29. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem;30:2785-2791.
30. Wang J.H., Smolyar A., Tan K., Liu J.H., Kim M., Sun Z.Y., Wagner G., Reinherz E.L. (1999) Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell;97:791-803.
31. Velikovsky C.A., Deng L., Chlewicki L.K., Fernandez M.M., Kumar V., Mariuzza R.A. (2007) Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family. Immunity;27:572-584.
32. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The Protein Data Bank. Nucleic Acids Res;28:235-242.
33. Brand D.D., Latham K.A., Rosloniec E.F. (2007) Collagen-induced arthritis. Nat Protoc;2:1269-1275.
34. Williams R.O. (2004) Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med;98:207-216.
35. Taneja V., Behrens M., Mangalam A., Griffiths M.M., Luthra H.S., David C.S. (2007) New humanized HLA-DR4-transgenic mice that mimic the sex bias of rheumatoid arthritis. Arthritis Rheum;56:69-78.
36. Vaucher Rde A., Velho Gewehr Cde C., Correa A.P., Sant'Anna V., Ferreira J., Brandelli A. (2011) Evaluation of the immunogenicity and in vivo toxicity of the antimicrobial peptide P34. Int J Pharm;421:94-98.
37. Khachigian L.M. (2006) Collagen antibody-induced arthritis. Nat Protoc;1:2512-2516.
38. Morgan M.E., Flierman R., van Duivenvoorde L.M., Witteveen H.J., van Ewijk W., van Laar J.M., de Vries R.R., Toes R.E. (2005) Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum;52:2212-2221.
39. Taneja V., Taneja N., Paisansinsup T., Behrens M., Griffiths M., Luthra H., David C.S. (2002) CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J Immunol;168:5867-5875.
40. Behrens M., Trejo T., Luthra H., Griffiths M., David C.S., Taneja V. (2010) Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice. J Autoimmun;35:1-9.
41. Taneja V., Taneja N., Behrens M., Griffiths M.M., Luthra H.S., David C.S. (2005) Requirement for CD28 may not be absolute for collagen-induced arthritis: study with HLA-DQ8 transgenic mice. J Immunol;174:1118-1125.
42. Suchard S.J., Stetsko D.K., Davis P.M., Skala S., Potin D., Launay M., Dhar T.G., Barrish J.C., Susulic V., Shuster D.J., McIntyre K.W., McKinnon M., Salter-Cid L. (2010) An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis. J Immunol;184:3917-3926.
43. Clarkson N.G., Brown M.H. (2009) Inhibition and activation by CD244 depends on CD2 and phospholipase C-gamma1. J Biol Chem;284:24725-24734.
44. Kannan K., Ortmann R.A., Kimpel D. (2005) Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology;12:167-181.
45. Bissonnette R., Langley R.G., Papp K., Matheson R., Toth D., Hultquist M., Geba G.P., White B. (2009) Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res;301:429-442.
46. Goeb V., Buch M.H., Vital E.M., Emery P. (2009) Costimulation blockade in rheumatic diseases: where we are? Curr Opin Rheumatol;21:244-250.
47. Beier K.C., Kallinich T., Hamelmann E. (2007) T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease. Eur Respir J;30:383-390.
48. Ford M.L., Larsen C.P. (2009) Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev;229:294-306.
49. Flanagan M.E., Blumenkopf T.A., Brissette W.H., Brown M.F., Casavant J.M., Shang-Poa C., Doty J.L., et al. (2010) Discovery of CP-690, 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem;53:8468-8484.
50. Swanson C.D., Akama-Garren E.H., Stein E.A., Petralia J.D., Ruiz P.J., Edalati A., Lindstrom T.M., Robinson W.H. (2012) Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. J Immunol;188:3513-3521.
51. Kim M., Sun Z.Y., Byron O., Campbell G., Wagner G., Wang J., Reinherz E.L. (2001) Molecular dissection of the CD2-CD58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional "hot spot". J Mol Biol;312:711-720.
52. Bender A.T., Spyvee M., Satoh T., Gershman B., Teceno T., Burgess L., Kumar V., Wu Y., Yang H., Ding Y., Akare S., Chen Q. (2013) Evaluation of a candidate anti-arthritic drug using the mouse collagen antibody induced arthritis model and clinically relevant biomarkers. Am J Transl Res;5:92-102.
53. Williams R.O. (2007) Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol;361:265-284.
54. Kallinich T., Beier K.C., Gelfand E.W., Kroczek R.A., Hamelmann E. (2005) Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. Clin Exp Allergy;35:1521-1534.
55. Kaumaya P.T., Foy K.C. (2012) Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol;8:961-987.